Zobrazeno 1 - 10
of 50
pro vyhledávání: '"James E. MacDougall"'
Autor:
James F, Howard, Richard J, Nowak, Gil I, Wolfe, Miriam L, Freimer, Tuan H, Vu, John L, Hinton, Michael, Benatar, Petra W, Duda, James E, MacDougall, Ramin, Farzaneh-Far, Henry J, Kaminski, Richard, Barohn, Mazen, Dimachkie, Mamatha, Pasnoor, Constantine, Farmakidis, Tina, Liu, Samantha, Colgan, Michael G, Benatar, Tulio, Bertorini, Rekha, Pillai, Robert, Henegar, Mark, Bromberg, Summer, Gibson, Teresa, Janecki, Miriam, Freimer, Bakri, Elsheikh, Paige, Matisak, Angela, Genge, Amanda, Guidon, William, David, Ali A, Habib, Veena, Mathew, Tahseen, Mozaffar, William, Hewitt, Deborah, Barnett, Patricia, Sullivan, Doreen, Ho, Rebecca E, Traub, Manisha, Chopra, Radwa, Aly, Elham, Bayat, Mohammad, Abu-Rub, Shaida, Khan, Dale, Lange, Shara, Holzberg, Bhupendra, Khatri, Emily, Lindman, Tayo, Olapo, Lisa M, Sershon, Robert P, Lisak, Evanthia, Bernitsas, Kelly, Jia, Rabia, Malik, Tiffany D, Lewis-Collins, Michael, Nicolle, Aditi, Sharma, Bhaskar, Roy, Joan, Nye, Michael, Pulley, Alan, Berger, Yasmeen, Shabbir, Amit, Sachdev, Kimberly, Patterson, Zaeem, Siddiqi, Mark, Sivak, Joan, Bratton, George, Small, Anem, Kohli, Mary, Fetter, Tuan, Vu, Lucy, Lam, Brittany, Harvey, Nicholas, Silvestri, Kara, Patrick, Karen, Zakalik, James, MacDougall, Angela, Pontius, Michelle, Hoarty
Publikováno v:
JAMA neurology. 77(5)
Importance Many patients with generalized myasthenia gravis (gMG) have substantial clinical disability, persistent disease burden, and adverse effects attributable to chronic immunosuppression. Therefore, there is a significant need for targeted, wel
Autor:
Anthony Lembo, Caroline B. Kurtz, M Currie, Jeffrey M. Johnston, James E. MacDougall, Brian E. Lacy, S J Shiff
Publikováno v:
Neurogastroenterology and Motility
Background US Food and Drug Administration (FDA) set a rigorous standard for defining patient responders in irritable bowel syndrome-C (IBS-C; i.e., FDA's Responder Endpoint) for regulatory approval. However, this endpoint's utility for health-care p
Autor:
Caroline B. Kurtz, James E. MacDougall, Eamonn Martin Quigley, Satish S.C. Rao, Jeffrey M. Johnston, Mark G. Currie, Bernard J. Lavins, S J Shiff
Publikováno v:
Clinical Gastroenterology and Hepatology. 12:616-623
BACKGROUND & AIMS: Patients with irritable bowel syndrome with constipation (IBS-C) have abdominal symptoms that vary in severity. Linaclotide, a guanylate cyclase-C agonist, improves abdominal and bowel symptoms in these patients. We examined the pr
Autor:
Paul Eng, Caroline B. Kurtz, Satish S.C. Rao, Mark G. Currie, James E. MacDougall, James Z. Shao, Susan M. Fox, Jeffrey M. Johnston, Harvey Schneier, Kelvin Shi, Bernard J. Lavins, S J Shiff, Xinwei D. Jia, Anthony Lembo
Publikováno v:
American Journal of Gastroenterology. 107:1714-1724
Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C).This phase 3, double-blind, paral
Autor:
James Z. Shao, Caroline B. Kurtz, Paul Eng, Jeffrey M. Johnston, James E. MacDougall, Harvey Schneier, Bernard J. Lavins, S J Shiff, Susan M. Fox, Donald A. Fitch, Brenda I. Jeglinski, Mark G. Currie, Xinwei D. Jia, Anthony Lembo
Publikováno v:
New England Journal of Medicine. 365:527-536
Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation.We conducted two randomized, 12-week, multicent
Autor:
Anthony Lembo, Valerie Williams, James E. MacDougall, Mark G. Currie, Bernard J. Lavins, Jeffrey M. Johnston, Michael Camilleri, Robyn T. Carson, S J Shiff, Caroline B. Kurtz, Lauren Nelson
Optimal clinical trial endpoints for irritable bowel syndrome with constipation (IBS-C) are uncertain.The objective of this article is to compare adequate relief (AR) to abdominal/bowel symptoms, global endpoints, and FDA and EMA responder criteria;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fb81f913d071df67221d650337ce94
https://europepmc.org/articles/PMC4315678/
https://europepmc.org/articles/PMC4315678/
Publikováno v:
Statistics in Medicine. 25:513-527
The linear mixed model has become a widely used tool for longitudinal analysis of continuous variables. The use of regression splines in these models offers the analyst additional flexibility in the formulation of descriptive analyses, exploratory an
Autor:
Caroline B. Kurtz, Valerie Williams, Jeffrey M. Johnston, Robyn T. Carson, Stavros Tourkodimitris, James E. MacDougall, Lauren Nelson, Mollie J. Baird, Sheri Fehnel
Publikováno v:
Clinical and Experimental Gastroenterology
Lauren M Nelson,1 Valerie SL Williams,1 Sheri E Fehnel,1 Robyn T Carson,2 James MacDougall,3 Mollie J Baird,3 Stavros Tourkodimitris,2 Caroline B Kurtz,3 Jeffrey M Johnston31RTI Health Solutions, Durham, NC, USA; 2Forest Research Institute, Jersey Ci
Publikováno v:
Preventive Medicine. 32:128-141
Background. Adolescent dating violence is a public health problem. The public health approach to prevention is to identify predictors of problem behaviors and develop interventions to eliminate or reduce those predictors with the intention of alterin
Autor:
Karl E. Bauman, James E. MacDougall, George Fletcher Linder, Vangie A. Foshee, Wendy F. Greene, Gary G. Koch
Publikováno v:
American Journal of Public Health. 90:1619-1622
OBJECTIVES: An earlier report described desirable 1-month follow-up effects of the Safe Dates program on psychological, physical, and sexual dating violence. Mediators of the program-behavior relationship also were identified. The present report desc